Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sqz Biotechnologies Company (SQZ)

Sqz Biotechnologies Company (SQZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,829
  • Shares Outstanding, K 29,491
  • Annual Sales, $ 21,480 K
  • Annual Income, $ -79,460 K
  • 60-Month Beta 2.34
  • Price/Sales 0.37
  • Price/Cash Flow N/A
  • Price/Book 0.32
Trade SQZ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.76
  • Most Recent Earnings $-0.60 on 05/10/23
  • Latest Earnings Date 08/03/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.60
  • Number of Estimates 2
  • High Estimate -0.54
  • Low Estimate -0.66
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2500 +74.00%
on 06/30/23
0.6100 -28.69%
on 06/06/23
-0.1650 (-27.50%)
since 06/02/23
3-Month
0.2500 +74.00%
on 06/30/23
0.6990 -37.77%
on 04/17/23
-0.1563 (-26.43%)
since 04/03/23
52-Week
0.2500 +74.00%
on 06/30/23
3.5600 -87.78%
on 08/12/22
-2.6650 (-85.97%)
since 07/01/22

Most Recent Stories

More News
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates

SQZ Biotechnologies Company (SQZ) delivered earnings and revenue surprises of -11.11% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SQZ : 0.4350 (+61.11%)
SYBX : 1.8700 (+1.63%)
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 17.15 (+0.06%)
SQZ : 0.4350 (+61.11%)
Stock Index Futures Climb as Investors Weigh Fed Comments, Rate Outlook

June S&P 500 futures (ESM23) are up +0.53%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.96% this morning after three major U.S. benchmark indices closed sharply lower on Wednesday as Federal Reserve...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
SQZ : 0.4350 (+61.11%)
KBH : 70.35 (+2.28%)
SCS : 12.60 (+0.88%)
CHWY : 16.19 (+1.76%)
IOT : 38.93 (+2.37%)
SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in...

SQZ : 0.4350 (+61.11%)
SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

SQZ : 0.4350 (+61.11%)
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is not in compliance with Section 802.01C...

SQZ : 0.4350 (+61.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such...

SQZ : 0.4350 (+61.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such...

SQZ : 0.4350 (+61.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such...

SQZ : 0.4350 (+61.11%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SQZ Biotechnologies Company ("SQZ" or the "Company") (NYSE: SQZ). Such...

SQZ : 0.4350 (+61.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company...

See More

Key Turning Points

3rd Resistance Point 0.7297
2nd Resistance Point 0.6487
1st Resistance Point 0.5419
Last Price 0.4350
1st Support Level 0.3541
2nd Support Level 0.2731
3rd Support Level 0.1663

See More

52-Week High 3.5600
Fibonacci 61.8% 2.2956
Fibonacci 50% 1.9050
Fibonacci 38.2% 1.5144
Last Price 0.4350
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar